CSPC Innovation Pharmaceutical
CSPC Innovation Pharmaceutical Co Ltd, operating as CSPC Xinhiss, is a Chinese pharmaceutical manufacturer producing caffeine APIs and functional health supplements. The company manufactures synthetic caffeine active pharmaceutical ingredients, health functional beverages, and oral prescription medicines under the CSPC group. Principal revenues derive from product sales of caffeine APIs directly to global beverage brands and pharmaceutical companies, alongside functional food sales. Core end markets encompass global soft drink bottlers, pharmaceutical developers, sports nutrition brand owners, and retail healthcare shoppers across China and international export markets. CSPC Innovation Pharmaceutical holds a market-leading global position as one of the world's largest manufacturers of caffeine active pharmaceutical ingredients. The company is headquartered in Shijiazhuang, China, and its common shares trade on the ChiNext board of the Shenzhen Stock Exchange.
4 of the funds FundTelligence covers report a position in CSPC Innovation Pharmaceutical.
- Legal name
- CSPC Innovation Pharmaceutical Co Ltd
- Sector
- Health Care
- Country
- China
- Funds holding it
- 4
Funds holding CSPC Innovation Pharmaceutical
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.02 % (full portfolio disclosed, September 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, September 2026)
- KLP AksjeFremvoksende Markeder Indeks — KLP · 0.0 % (full portfolio disclosed, June 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.0 % (full portfolio disclosed, October 2026)